HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))

a neurotoxic quaternary haloperidol metabolite in rat liver; structure in first source
Also Known As:
HPP(+); BCPP(+); 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)pyridinium; 4-CFOBP; N-(4'-fluorobutyrophenone)-4-(4-chlorophenyl)pyridinium chloride; N-(4'-fluorobutyrophenone)-4-(4-chlorophenyl)pyridinium iodide; N-(4'-fluorobutyrophenone)-4-(4-chlorophenyl)pyridinium perchlorate
Networked: 780 relevant articles (23 outcomes, 85 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Whyte, Michael P: 34 articles (01/2022 - 06/2006)
2. Millán, José Luis: 20 articles (12/2021 - 06/2008)
3. Mumm, Steven: 16 articles (01/2020 - 06/2006)
4. Michigami, Toshimi: 13 articles (09/2021 - 01/2012)
5. Ozono, Keiichi: 13 articles (12/2020 - 01/2016)
6. Mornet, Etienne: 12 articles (01/2021 - 06/2009)
7. Jakob, Franz: 11 articles (05/2021 - 10/2014)
8. Watanabe, Atsushi: 11 articles (12/2020 - 02/2011)
9. Rockman-Greenberg, Cheryl: 10 articles (01/2022 - 06/2013)
10. Narisawa, Sonoko: 10 articles (12/2021 - 06/2008)

Related Diseases

1. Hypophosphatasia
2. Pain (Aches)
01/01/2023 - "The skeletal group had a higher median age at baseline (50.1 vs 44.4 y; P=0.047) but a lower median age at first HPP manifestation (12.3 vs 22.1 y; P=0.0473), with more signs and symptoms (median, 4 vs 3; P<0.0001) and involved body systems (median, 3 vs 2; P<0.0001) than the muscular/pain group. "
01/01/2023 - "Baseline/pretreatment demographic, clinical characteristic, and patient-reported disability/health-related quality-of-life (HRQoL) data from adults (≥18 y) in the Global HPP Registry (NCT02306720) were stratified by presence of overt skeletal manifestations (skeletal group) versus muscular/pain manifestations without skeletal manifestations (muscular/pain group) and summarized descriptively. "
12/01/2022 - "We conducted a cross-sectional study assessing biochemical parameters, fracture prevalence, bone mineral density (BMD), bone turnover markers, physical performance and pain characteristics in 40 adults with HPP and 40 sex-, age-, BMI- and menopausal status-matched healthy controls. "
01/01/2022 - "Along with the more classical skeletal signs and symptoms, pain, muscular, and constitutional/metabolic manifestations are common in adults with HPP, regardless of age of disease onset, highlighting a full spectrum of HPP manifestations."
01/01/2022 - "The treated, pediatric-onset patients were more likely to have a history of pain (prevalence ratio [PR]: 1.3, 95% confidence interval [CI] 1.1, 1.4), skeletal (PR: 1.3, 95% CI 1.1, 1.6), constitutional/metabolic (PR: 1.7, 95% CI 1.3, 2.0), muscular (PR: 1.8, 95% CI 1.4, 2.1) and neurological (PR: 1.7, 95% CI 1.1, 2.3) manifestations of HPP, and also had poorer measures for health-related quality of life, pain, and disability compared with untreated pediatric-onset patients. "
3. Hypertension (High Blood Pressure)
4. Neoplasms (Cancer)
5. Breast Neoplasms (Breast Cancer)

Related Drugs and Biologics

1. asfotase alfa
2. Alkaline Phosphatase
3. Allopurinol (Remid)
4. Fluorouracil (Carac)
5. Polysaccharides (Glycans)
6. Enzymes
7. Hyaluronic Acid (Hyaluronan)
8. Proteins (Proteins, Gene)
9. Minerals
10. Melphalan (Alkeran)

Related Therapies and Procedures

1. Therapeutics
2. Enzyme Replacement Therapy
3. Combination Drug Therapy (Combination Chemotherapy)
4. Baths
5. Drug Therapy (Chemotherapy)